Is lipoprotein(a) an independent risk factor in PCSK9 inhibitor outcomes studies?
Lead ODYSSEY Outcomes Investigator Professor Gregory Schwartz (University of Colorado, Aurora, USA) discusses the latest data
Listen to the presentation here »
Dr Erin Bohula (Brigham and Women’s Hospital and Harvard Medical School, Boston, USA) discusses data from the FOURIER trial
What’s new about lipoprotein(a) genetics and cardiovascular risk?
Professor Anne Tybjaerg-Hansen (University of Copenhagen, Denmark) discusses the data
